证券代码：002370 证券简称：亚太药业 公告编号：2025-065 浙江亚太药业股份有限公司 关于第八届董事会第四次会议决议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、董事会会议通知的时间和方式 浙江亚太药业股份有限公司（以下简称"公司"）第八届董事会 第四次会议（以下简称"会议"）通知于 2025 年 8 月 18 日以专人送 达、微信等方式送达各位董事。 2、召开董事会会议的时间、地点和方式 会议于 2025 年 8 月 28 日在公司办公楼三楼会议室以现场表决与 通讯表决相结合的方式召开。 3、董事会会议出席情况 公司监事会就该事项发表意见，具体内容详见 2025 年 8 月 30 日 的巨潮资讯网（www.cninfo.com.cn）。 （二）以 9 票同意，0 票反对，0 票弃权，审议通过了《2025 年 半年度报告及其摘要》 本议案已经公司审计委员会审议通过。 本次会议的应表决董事 9 人，实际参与表决董事 9 人，其中董事 宋令波先生以通讯方式参与表决，公司监事、高级管理人员列席会议。 4、会议由董事长 ...

金融界消息 截至2025年8月25日收盘，亚太药业（002370）报收于6.77元，上涨0.59%，换手率9.74%， 成交量72.60万手，成交金额4.91亿元。 资金流向方面，今日主力资金净流出2507.96万元，占比成交额5.11%。其中，超大单净流出845.11万 元、占成交额1.72%，大单净流出1662.85万元、占成交额3.39%，中单净流出流入1111.59万元、占成交 额2.27%，小单净流入1396.37万元、占成交额2.85%。 亚太药业最新一期业绩显示，截至2025一季报，公司营业总收入6455.05万元、同比减少42.73%，归属 净利润780.32万元，同比减少160.25%，扣非净利润756.38万元，同比减少242.05%，流动比率2.333、速 动比率2.147、资产负债率30.75%。 天眼查商业履历信息显示，浙江亚太药业股份有限公司，成立于2001年，位于绍兴市，是一家以从事医 药制造业为主的企业。企业注册资本74566.753万人民币，实缴资本60917.106万人民币。公司法定代表 人为岑建维。 通过天眼查大数据分析，浙江亚太药业股份有限公司共对外投资了7家企业，参与 ...

Group 1 - The stock price of Asia Pacific Pharmaceutical reached 7.28 yuan as of the close on August 18, 2025, reflecting a 1.82% increase from the previous trading day [1] - The stock opened at 7.30 yuan, with a high of 7.30 yuan and a low of 7.00 yuan, with a trading volume of 17.25 million hands and a transaction amount of 1.225 billion yuan [1] - The company is primarily engaged in the research, development, production, and sales of chemical pharmaceuticals, covering various therapeutic areas including anti-infective, digestive system, and cardiovascular [1] Group 2 - On the morning of August 18, Asia Pacific Pharmaceutical experienced a rapid pullback, with a drop of over 2% within five minutes around 9:30 AM, reaching a low of 7.15 yuan [1] - The net outflow of main funds on that day was 52.82 million yuan, with a cumulative net outflow of 140 million yuan over the past five trading days [1]

Group 1 - The core viewpoint of the news indicates that Asia-Pacific Pharmaceutical (002370) experienced a decline in stock price, closing at 6.8 yuan, down 2.16% as of August 14, 2025 [1] - The trading volume was 1,405,800 hands, with a transaction amount of 982 million yuan [1] - The net outflow of main funds was 23.09 million yuan, accounting for 2.35% of the transaction amount, with significant outflows from large orders [1] Group 2 - The latest financial performance of Asia-Pacific Pharmaceutical shows total operating revenue of 64.55 million yuan, a year-on-year decrease of 42.73% [1] - The net profit attributable to shareholders was 7.80 million yuan, down 160.25% year-on-year, while the non-recurring net profit was 7.56 million yuan, a decrease of 242.05% [1] - The company has a current ratio of 2.333, a quick ratio of 2.147, and a debt-to-asset ratio of 30.75% [1] Group 3 - Asia-Pacific Pharmaceutical, established in 2001 and located in Shaoxing, primarily engages in the pharmaceutical manufacturing industry [2] - The company has made investments in 7 enterprises and participated in 725 bidding projects [2] - It holds 120 trademark registrations and 78 patents, along with 135 administrative licenses [2]

Group 1 - The stock price of Asia Pacific Pharmaceutical as of August 6, 2025, is 7.17 yuan, down 3.5% from the previous trading day, with a trading volume of 1.681 billion yuan and a turnover rate of 30.37% [1] - The stock experienced significant volatility during the day, reaching a high of 7.75 yuan and a low of 7.03 yuan, resulting in an amplitude of 9.69% [1] - Asia Pacific Pharmaceutical operates in the chemical pharmaceutical sector, focusing on drug research, production, and sales, with key products including anti-infection drugs and gastrointestinal medications [1] Group 2 - In the early morning of August 6, the stock price of Asia Pacific Pharmaceutical quickly retraced, dropping over 2% within five minutes, with a minimum price of 7.48 yuan and a trading volume of 573 million yuan [1] - On August 6, the net outflow of main funds was 44.7413 million yuan, accounting for 0.84% of the circulating market value, while the cumulative net outflow over the past five trading days reached 310 million yuan, representing 5.79% of the circulating market value [1]

亚太药业今日下跌8.16%，全天换手率32.79%，成交额18.56亿元，振幅6.08%。龙虎榜数据显示，机构 净卖出1787.29万元，营业部席位合计净卖出5241.72万元。 深交所公开信息显示，当日该股因日跌幅偏离值达-8.93%上榜，机构专用席位净卖出1787.29万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交2.69亿元，其中，买入成交额为9928.02 万元，卖出成交额为1.70亿元，合计净卖出7029.02万元。 具体来看，今日上榜的营业部中，共有1家机构专用席位现身，即卖三，合计净卖出1787.29万元。 近半年该股累计上榜龙虎榜9次，上榜次日股价平均涨4.30%，上榜后5日平均涨11.47%。 资金流向方面，今日该股主力资金净流出1.92亿元，其中，特大单净流出1.04亿元，大单资金净流出 8876.79万元。近5日主力资金净流出3.57亿元。（数据宝） 亚太药业8月5日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 国信证券股份有限公司 ...

Group 1 - The Helicobacter pylori concept sector declined by 0.50%, ranking among the top declines in concept sectors, with notable declines in stocks such as Keta Bio, Anglikang, and Asia-Pacific Pharmaceutical [1][2] - Among the 49 stocks in the Helicobacter pylori concept sector, 27 stocks saw price increases, with Zhongheng Group, Hanyu Pharmaceutical, and *ST Sansheng leading the gains at 9.85%, 5.63%, and 5.05% respectively [1][4] - The Helicobacter pylori concept sector experienced a net outflow of 1.725 billion yuan in main funds, with Hanyu Pharmaceutical seeing the largest outflow of 909.33 million yuan [2][3] Group 2 - The top gainers in the concept sectors included the Armament Reorganization concept at 6.12%, PEEK materials at 4.11%, and Brain-Computer Interface at 2.72% [2] - The main funds saw inflows in stocks such as Zhongheng Group, Baicheng Pharmaceutical, and Asia Treasure Pharmaceutical, with inflows of 88.23 million yuan, 63.86 million yuan, and 19.51 million yuan respectively [2][4] - The stocks with the largest net outflows in the Helicobacter pylori concept included Asia-Pacific Pharmaceutical at -8.16%, Keta Bio at -10.28%, and Anglikang at -9.46% [2][3]

Market Performance - As of August 5, the generic drug consistency evaluation concept declined by 0.55%, ranking among the top declines in the concept sector [1] - Within the sector, notable declines were seen in companies such as Angli Kang, Asia-Pacific Pharmaceutical, and Nanxin Pharmaceutical, while 46 stocks experienced price increases, with Chengyi Pharmaceutical, Guilin Sanjin, and Zhongheng Group leading with increases of 10.04%, 10.00%, and 9.85% respectively [1] Capital Flow - The generic drug consistency evaluation sector saw a net outflow of 3.403 billion yuan, with 112 stocks experiencing net outflows, and 5 stocks seeing outflows exceeding 100 million yuan [2] - The stock with the highest net outflow was Hanyu Pharmaceutical, with a net outflow of 909.3 million yuan, followed by Asia-Pacific Pharmaceutical, Guangsheng Tang, and Yipinhong with net outflows of 192.45 million yuan, 135.13 million yuan, and 119.26 million yuan respectively [2] Top Gainers and Losers - The top gainers in the sector included Chengyi Pharmaceutical, Guilin Sanjin, and Zhongheng Group, with respective net inflows of 102 million yuan, 94.85 million yuan, and 88.22 million yuan [6] - Conversely, the top losers included Hanyu Pharmaceutical, Asia-Pacific Pharmaceutical, and Guangsheng Tang, with significant net outflows [2][3]

Market Overview - On August 4, the market saw a significant rise with all three major indices closing in the green, over 3,800 stocks rising, and more than 1,300 stocks declining [1] - A total of 69 stocks hit the daily limit up, while 6 stocks hit the limit down [1] High-Performing Stocks - Victory Energy achieved a limit up for four consecutive days, while Lideman, involved in a merger and restructuring, saw a 20% limit up for three consecutive days [3][4] - The military industry sector had nearly 20 stocks hitting limit up or rising over 10%, with notable performances from Wanze Shares and Great Wall Military [3] - The robotics sector also experienced a rebound, with Zhongma Transmission and Dongjie Intelligent showing strong performances [3] Stock Performance Data - Victory Energy (Code: 001331) recorded a 10.01% increase, with a trading volume of 6.0748 billion [4] - Dongxin Co. (Code: 688110) saw a 20% increase, with a trading volume of 5.667 billion [4] - Lideman (Code: 300289) achieved a 20% increase, with a trading volume of 1.588 billion [4] Top Trading Stocks - The top net buying stocks on the day included Hanyu Pharmaceutical, Construction Industry, and Longcheng Military, with net purchases of 5.45 billion, 4.57 billion, and 4.45 billion respectively [5][6] - The top net selling stocks included Giant Network, Asia-Pacific Pharmaceutical, and Tibet Tianlu, with net sales of 2.07 billion, 1.93 billion, and 1.78 billion respectively [7] Sector Highlights - Hanyu Pharmaceutical is collaborating with a well-known cryptocurrency exchange, marking a significant move in the pharmaceutical industry by tokenizing future revenue rights [10][12] - The company is advancing its innovative weight-loss drug project, with various formulations under development [12] - Construction Industry, involved in military restructuring, also saw significant trading activity, with a trading volume of 3.249 billion [13][16] Institutional Activity - Institutions showed strong interest in Hanyu Pharmaceutical and Construction Industry, with net purchases of 2.33 billion and 2.17 billion respectively [20] - Conversely, institutions sold off shares in Giant Network and Asia-Pacific Pharmaceutical, with net sales of 1.76 billion and 1.25 billion respectively [20]

深交所公开信息显示，当日该股因日换手率达43.15%上榜，机构专用席位净卖出1.25亿元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交4.74亿元，其中，买入成交额为1.41亿 元，卖出成交额为3.33亿元，合计净卖出1.93亿元。 具体来看，今日上榜的营业部中，共有2家机构专用席位现身，即卖一、卖二，合计买入金额1214.01万 元，卖出金额1.37亿元，合计净卖出1.25亿元。 近半年该股累计上榜龙虎榜8次，上榜次日股价平均涨6.08%，上榜后5日平均涨19.65%。 亚太药业今日上涨9.32%，全天换手率43.15%，成交额24.49亿元，振幅13.06%。龙虎榜数据显示，机构 净卖出1.25亿元，营业部席位合计净卖出6736.68万元。 资金流向方面，今日该股主力资金净流出1.43亿元，其中，特大单净流出6512.39万元，大单资金净流出 7790.25万元。近5日主力资金净流出2.07亿元。（数据宝） 亚太药业8月4日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 中国银河 ...